NCT07217015Phase 2Active not recruiting

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

Study sponsor: Kymera Therapeutics, Inc. · KYMR

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-06Estimated
Enrollment · participants200Estimated
Source updated2026-10-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source